Detailed physiological characterization of the development of type 2 diabetes in Hispanic women with prior gestational diabetes mellitus

Anny H Xiang, Siri L Kjos, Miwa Takayanagi, Enrique Trigo, Thomas A Buchanan, Anny H Xiang, Siri L Kjos, Miwa Takayanagi, Enrique Trigo, Thomas A Buchanan

Abstract

Objective: To identify physiological and clinical variables associated with development of type 2 diabetes up to 12 years after pregnancies complicated by gestational diabetes.

Research design and methods: Seventy-two islet cell antibody-negative nondiabetic Hispanic women had oral (oGTT) and intravenous (ivGTT) glucose tolerance tests, glucose clamps, and body composition assessed between 15 and 30 months after pregnancies complicated by gestational diabetes mellitus (GDM). They returned for oGTTs at 15-month intervals until they dropped out, developed diabetes, or reached 12 years postpartum. Cox regression analysis was used to identify baseline predictors and changes during follow-up that were associated with development of type 2 diabetes.

Results: At baseline, relatively low insulin sensitivity, insulin response, and β-cell compensation for insulin resistance were independently associated with development of diabetes. During follow-up, weight and fat gain and rates of decline in β-cell compensation were significantly associated with diabetes, while additional pregnancy and use of progestin-only contraception were marginally associated with diabetes risk.

Conclusions: In Hispanic women, GDM represents detection of a chronic disease process characterized by falling β-cell compensation for chronic insulin resistance. Women who are farthest along at diagnosis and/or deteriorating most rapidly are most likely to develop type 2 diabetes within 12 years after the index pregnancy. Weight gain, additional pregnancy, and progestin-only contraception are potential modifiable factors that increase diabetes risk.

Figures

FIG. 1.
FIG. 1.
Kaplan-Meier plot of diabetes cumulative incidence rate in 72 women without diabetes at entry and with at least one follow-up oGTT. Vertical lines are 95% CIs. The numbers given by the Subjects line included subjects who developed diabetes and who were under follow-up without diabetes by the corresponding follow-up years.
FIG. 2.
FIG. 2.
A: Baseline disposition index and 95% CIs according to final diabetes status during the entire follow-up (left two bars) or within 5 years and >5 years after the index pregnancy (right two bars). B: Disposition index during follow-up in women who developed diabetes and in women who remained diabetes free. Data are plotted relative to end points of diabetes or final visit without diabetes. Numbers shown above/below the lines are the corresponding sample sizes. Log scale is depicted to reflect that data were log transformed prior to all data analysis; geometric means are presented.

References

    1. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes. Diabetes Care 2002;25:1862–1868
    1. Catalano PM, Huston L, Amini SB, Kalhan SC. Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes Am J Obstet Gynecol 1999;180:903–916
    1. Homko C, Sivan E, Chen X, Reece EA, Boden G. Insulin secretion during and after pregnancy in patients with gestational diabetes mellitus. J Clin Endocrinol Metab 2001;86:568–573
    1. Buchanan TA, Xiang AH, Kjos SL, Watanabe RM. What is gestational diabetes? Diabetes Care 30(Suppl. 2):S105–S111, 2007
    1. Xiang AH, Wang C, Peters RK, Trigo E, Kjos SL, Buchanan TA. Coordinate changes in plasma glucose and pancreatic β-cell function in Latino women at high risk for type 2 diabetes. Diabetes 2006;55:1074–1079
    1. Xiang AH, Peters RK, Trigo E, Kjos SL, Lee WP, Buchanan TA. Multiple metabolic defects during late pregnancy in women at high risk for type 2 diabetes mellitus. Diabetes 1999;48:848–854
    1. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27(Suppl. 1):S5–S10
    1. Bergman RN. Toward a physiological understanding of glucose tolerance: minimal model approach. Diabetes 1989;38:1512–1528
    1. Kotler DP, Burastero S, Wang J, Pierson RN., Jr Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: effects of race, sex, and disease. Am J Clin Nutr 1996;64(Suppl. 3):S489–S497
    1. Peters RK, Kjos SL, Xiang A, Buchanan TA. Long-term diabetogenic effect of a single pregnancy in women with prior gestational diabetes mellitus. Lancet 1996;347:227–230
    1. Xiang AH, Kawakubo M, Trigo E, Kjos SL, Buchanan TA. Declining β-cell compensation for insulin resistance in Hispanic women with recent gestational diabetes mellitus: association with changes in weight, adiponectin, and C-reactive protein. Diabetes Care 2010;33:396–401
    1. Weyer C, Hanson K, Bogardus C, Pratley R. Long-term changes in insulin action and insulin secretion associated with weight gain, loss, regain and maintenance of body weight. Diabetologia 2000;43:36–46
    1. Kriketos AD, Carey DG, Jenkins AB, Chisholm DJ, Furler SM, Campbell LV. Central fat predicts deterioration of insulin secretion index and fasting glycemia: 6-year follow-up of subjects at varying risk of type 2 diabetes. Diabet Med 2003;294–300
    1. Kjos SL, Peters RK, Xiang A, Thomas D, Schafer U, Buchanan TA. Oral contraception and the risk of type 2 diabetes in Latino women with prior gestational diabetes. JAMA 1998;280:533–538
    1. Xiang AH, Kawakubo M, Kjos SL, Buchanan TA. Long-acting injectable progestin contraception and risk of type 2 diabetes in Latino women with prior gestational diabetes mellitus. Diabetes Care 2006;29:613–617
    1. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP. Preservation of pancreatic B-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796–2803
    1. Xiang A, Peters RK, Kjos SL, Marroqiun A, Goico J, Ochoa C, Kawakubo M, Buchanan TA. Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006;55:517–522

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner